We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Batm Advanced Communications Ld | LSE:BVC | London | Ordinary Share | IL0010849045 | ORD ILS0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 0.51% | 19.75 | 18.35 | 19.80 | 19.75 | 19.75 | 19.75 | 84,807 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Communications Services, Nec | 122.83M | -193k | -0.0004 | -493.75 | 86.12M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/9/2018 14:22 | Simon Thompson August 29, 2018 BATM Advanced Communications (BVC:38.5p), a £155m market cap provider of medical laboratory systems and network solutions, and a constituent of my 2017 Bargain Shares Portfolio, has delivered the bullish half-year results I had anticipated in early summer ('Profit from 5GM with BATM', 8 Jun 2018). BATM continues to make significant progress monetising its intellectual property, which is why the share price has risen by almost half since that article, and doubled on my 19.25p entry point in just 18 months. There should be more upside to come as investors have yet to cotton onto BATM’s joint venture, Ador, with Netherlands-based private group Gamida. Ador will start shipments next year of its novel molecular diagnostic platform that fully automates the rapid analysis of nucleic acid samples and delivers results in less than 90 minutes. It is being targeted at screening for hospital-acquired infections such as MRSA, and C. Diff, a leading cause of morbidity and mortality; and to identify tropical infections in travellers returning home with fevers, some of which can be life threatening and need early and accurate diagnosis. The patent protected bench-top analyser can probe 100 targets in a single proprietary carbon array whereas current products only probe on average between four to six targets per test sample. Chief executive Dr Zvi Marom believes it will “make a big splash” when launched next year. He has a point as the value of the IP to a big player such as Abbott Laboratories or Roche Diagnostics could be in excess of BATM’s current market value. Equally exciting is the joint development agreement (JDA) with Arm Holdings to develop and market infrastructure solutions for virtual network functions, a technology that will play a critical role in supporting the services of 5G network operators and run applications such as autonomous vehicles. BATM has already conducted successful proof-of-concept trials with tier 1 and 2 telecom operators and will book sales from them in the second half. Moreover, with its strong order book buoyed by demand from government agencies in cyber security protection, the balance sheet cash-rich – net funds of $16.9m (£13.1m) will be boosted by a $3.2m windfall from the disposal of a legacy asset – and analyst estimates not fully factoring in a likely multimillion dollar royalty stream from the Arm Holdings JDA, then an my raised 50p target price (based on an enterprise value to cash profit multiple of 30 for the 2020 financial year) could yet prove conservative. Buy. | reeltime | |
31/8/2018 07:08 | Expecting to move from 50/50 split to 60/40, I assume towards the tech/cyber side, so there is huge growth in this side of the business. Expect even stronger demand with 5G roll out, so long term prospects are good. | paulisi | |
30/8/2018 09:54 | That's quite a positive update on 'Pro' for all divisions. Attractive company. imo | owenski | |
30/8/2018 09:14 | Zvi interviewed: .. | james dean | |
29/8/2018 15:19 | If Simon Thompson is very, very positive, so am i | mr hangman | |
29/8/2018 14:48 | >miti 100. The medical arm of BATM is a bit outside my technical understanding. The medical portfolio was started by them to smooth out the erratic nature of the Telco supply business. It appears to have made sense but To be honest with you I thought they would have sold the division. I don't invest in Bio Tech. The tie up though on the face of it seems almost too good to be true and I would be pushed to try to value it. It could deliver revenue though in the near term so its another major plus previously not on the table. | fse | |
29/8/2018 14:45 | That got bought up quite nicely. | owenski | |
29/8/2018 13:16 | ST "my raised 50p target price could yet prove conservative.Buy" | wynmck | |
29/8/2018 13:14 | Nice little tree shake! | gbenson1 | |
29/8/2018 12:36 | ST update - very, very positive | mirabeau | |
29/8/2018 12:25 | FSE , What's your unbiased view on the ADOR joint venture ? TIA. | miti 1000 | |
29/8/2018 10:52 | No press, think it's just a few investors taking something off the table, there must have been an element of 7-10 % gain investors on the rise up? | gbenson1 | |
29/8/2018 10:49 | It normally drops on results day, so no surprise. I guess BATM is still to prove it can actually make a profit. They seem closer to realising this but hey, still loss making. | picsous | |
29/8/2018 10:35 | Any reason for the sharp drop? | volsung | |
28/8/2018 22:46 | FSE, ST will be speaking to Zvi Marom tomorrow am and posting his thoughts thereafter in IC. | miti 1000 | |
28/8/2018 20:01 | Thanks JD much appreciated maybe they read what I sent them, cant find the update on Shore own site but what the heck at least they have done it. My own expectation for full year 2018 is for 118M so I feel certain they will break 114M expectation for this year. Range (my estimate) 114M to 122M. Its really a matter of whether they can convert the various POC's into actual sales and seeing as they have a plethora of them on tap that seems achievable. Be interesting to see if ST has any comments. | fse | |
28/8/2018 18:57 | Shore Capital hikes FY estimate House broker Shore Capital responded to the interims by tweaking its full-year revenue forecast. “With a stronger revenue performance than our trend expectation for H1, we are increasing our FY estimate by US$2mln to US$114mln, but retaining EBITDA, PBT and EPS estimates for the moment, reflecting the continuing operational investment focus of management,” Shore said. “The second half promises further strong development; we look for the emergence of positive operational leverage, returning BATM to profitability and good free cash generation over our forecast horizon. BATM, in our view, continues to transition its technology platforms to next-generation infrastructures across group activities; underlying operational strength is yet to show in financial results, but we note underlying momentum,” the broker added. Shore said the group is exposed to a number of “growth themes” across medical equipment, testing & diagnostics and virtual network management (5G infrastructures), network software and cyber skills & technologies within networks. BATM’s intellectual property (IP) covers all of the above fields and increasingly the company is finding ways to make money out of its IP. Shares in BATM were down 0.1p at 41p in mid-morning trade .. | james dean | |
28/8/2018 16:46 | Of note: " As a result, the Group is confident of achieving year-on-year growth for full year 2018, in line with market expectations." Problem here is that the house broker would normally issue a statement in conjunction with the company giving guidance as to what these "expectations" are. Shore Capital have given no such guidance and are still to retract their last set of inaccurate figures from a year ago. BUT.... IC came to the rescue and ST has the scoop on BATM. FWIW I agree with ST's comments on BATM particularly as they are unbiased and he has them in his portfolio still....... | fse | |
28/8/2018 15:41 | These results are a mixed bag the main positives are increases in revenue across the board. The company is now in growth mode and these results and forward looking statements underpin the current share price On the medical side the problems in the diagnostics units appear to have been addressed and we are told the situation in China has improved. There are some encouraging new product details mentioned. The sterilizer and mobile agricultural units are making progress although I am not sure what the size of this market or its potential is so doubt it will be a huge game changer but its contributing nevertheless. I agree that it would have been nice to have seen some better spin from the cyber business and this an area of potential very high growth. Most of the detail here is going to be classified and there are POC trials running. Still they are selling solutions into this market. BATM Telco are attracting new investors largely due to the tie up with ARM. The company is growing "without" any contribution from this partnership at this point in time. ....BATM must be getting taken very seriously and 5G will change the world as we know it......... " Post period, the Group achieved the first milestone under its agreement with Arm by entering into a non-exclusive partnership with FatPipe Networks ("FatPipe"), a leading provider of Software-Defined Wide-Area Networks (SD-WAN) and hybrid WANs, to provide a hardware/software agnostic solution offering real-time SD-WAN VNF services. This represents the first solution to be delivered under the Group's agreement with Arm." | fse | |
28/8/2018 13:24 | Nice to see some recovery in the few underperforming areas such as diagnostics where Chinese demand is picking up. A few more govt cyber orders would have been nice but perhaps we are still in POC stage . Clearly , NFV functionality with Arm and Intel is crucial going forwards and its these sales which will be imperative for share price appreciation . 'During the period, the Group conducted successful NFV proof-of-concept trials with various tier 1 and 2 customers worldwide, which it expects to translate to sales in H2 2018.' | miti 1000 | |
28/8/2018 12:42 | Results were solid lots of potential for the future. I normally follows share according to their buy volume, I've been in BATM for decades, the recent increase in buying volume since early Jun leads me to think someone is building a stake around the 40-41p area, I expect a breakout to 45p+ in the next 7-10 days! | gbenson1 | |
28/8/2018 12:23 | We normally see a big drop in the share price on results day, what's changed? | picsous | |
28/8/2018 11:32 | I particularly like this line.... "The Group is the only worldwide software vendor to provide NFV functionality to Arm architecture and all Intel platforms." Very encouraging reading (for a change) . | spekky | |
28/8/2018 09:43 | I'm pleased to see the share price higher after holding for many many years but I still believe this company has some great products and could be much more successful with commercially oriented Board. In the grand scheme of things this is a small company and should be running a much leaner cost base. Admin and S/M costs are in my view too high | car1pet |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions